ArticleScientific reports2025
Evaluation of clinical biomarkers for differential diagnosis of intravascular lymphoma and Still's disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravascular lymphoma (IVL) and Still's disease are rare conditions that present with overlapping systemic symptoms, including persistent fever and inflammatory responses, making differential diagnosis challenging. Misdiagnosis can lead to delays in appropriate treatment, which is particularly critical for IVL due to its aggressive nature. This retrospective cohort study aimed to identify clinically useful biomarkers for distinguishing IVL from Still's disease. IVL and Still's disease patients were analyzed alongside healthy controls. Laboratory assessments included serum ferritin, soluble interleukin-2 receptor (sIL-2R), and interleukin-18 (IL-18) levels. Ferritin levels were significantly higher in Still's disease, while sIL-2R levels were markedly elevated in IVL. IL-18 levels were significantly higher in Still's disease than in IVL, distinguishing the inflammatory profile of each disease. Receiver operating characteristic curve analysis demonstrated excellent discriminatory power, with sIL-2R and IL-18 achieving an area under the curve. These findings suggest that ferritin, sIL-2R, and IL-18 serve as potential biomarkers in differentiating IVL from Still's disease. Their incorporation into clinical practice may facilitate early and accurate diagnosis, reducing the risk of misdiagnosis and improving patient outcomes. Further large-scale studies are warranted to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.